Torcetrapib

After 16 years and nearly $800 million in research, Pfizer halted development of a Lipitor successor called torcetrapib because of patient deaths in trials. ❋ Jonathan D. Rockoff (2011)

A compound called torcetrapib raised so-called good cholesterol, and Pfizer championed it—right up to the moment that a board monitoring the testing learned it was increasing patients' risk of dying. ❋ Jonathan D. Rockoff (2011)

Pfizer abruptly halted development of a similar drug called torcetrapib four years ago, in an $800 million debacle. ❋ Ron Winslow (2010)

"He was dealt a difficult hand when a promising cholesterol drug called torcetrapib failed and there was no successor to Lipitor," Funtleyder said, adding, "He might have done a better job." ❋ By LINDA A. JOHNSON (2010)

The company had banked on another cholesterol-lowering drug, called torcetrapib, to provide a new source of growth. ❋ Unknown (2008)

Late last year, Pfizer lost its brightest hope on this front, a drug called torcetrapib that raised so-called good cholesterol and was personally championed by Mr. LaMattina, after that drug was linked to safety problems in premarket tests. ❋ Unknown (2007)

But much of the focus in Pfizer's pipeline is on a single drug, torcetrapib, which is designed to raise good cholesterol and clear plaque out of arteries. ❋ Matthew Herper (2006)

Kindler was most excited about a new drug called torcetrapib, which had recently entered Phase III clinical trials, the last step before filing for FDA approval. ❋ Jmckeel (2012)

Neither drug caused high blood pressure, a problem that helped doom Pfizer's own CETP inhibitor, called torcetrapib. ❋ Unknown (2011)

It is still early days for dalcetrapib, and medical experts remain wary following the high-profile failure of a similar drug from Pfizer called torcetrapib.

It is still early days for dalcetrapib, and medical experts remain wary following the high-profile failure of a similar drug from Pfizer, called torcetrapib, in 2006. ❋ Unknown (2011)

"He was dealt a difficult hand when a promising cholesterol drug called torcetrapib failed and there was no successor to Lipitor," Mr. Funtleyder said, adding, "He might have done a better job." ❋ LINDA A. JOHNSON (2010)